Tributyrin for mild Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This trial tests whether a supplement called tributyrin, which may help the gut and brain, can improve symptoms in people with mild Alzheimer's disease. It aims to see if boosting certain gut chemicals can slow the disease's progress.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with mild Alzheimer's disease within the last year.
- You are willing to take part and sign a consent form.
- You are not currently in another clinical trial.
- You do not have other causes of dementia (like head injury, brain tumor, epilepsy, or brain infection).
- You have not recently taken immunosuppressants, steroids, antibiotics, or chemotherapy in the past month.
- You do not have gastrointestinal (stomach or gut) disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a supplement called tributyrin to see if it can help with thinking and memory problems in people with Parkinson's disease. You may be able to join if you have both Parkinson's and mild cognitive impairment or dementia.
This trial tests whether a special form of a dietary fat called tricaprilin can help people with mild-to-moderate Alzheimer's disease. It may provide an alternative or add-on to current treatments to help with memory and thinking.
This trial tests whether a supplement called Neuroaid II can help people with mild to moderate Alzheimer's disease. It is a pill taken alongside your usual Alzheimer's treatments, and the study aims to see if it can slow down memory decline.
This trial tests whether a natural plant compound can help support memory and thinking in people at higher risk for Alzheimer's disease. You may qualify if you are over 50, overweight, eat a typical Western diet, and have a family history of Alzheimer's.
This program provides access to an investigational drug called TB006 for people with Alzheimer's disease or related dementias who have run out of standard treatment options. It aims to see if the drug is safe and helpful in a real-world setting.
This trial tests a new drug, NBI-1117567, for people with mild to moderate Alzheimer's disease who are already taking a standard Alzheimer's medication. The goal is to see if the new drug can help improve symptoms.
Hear when a new Alzheimer Disease (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.